Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

184 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Value of 18F-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in non-small-cell lung cancer for prediction of pathologic response and times to relapse after neoadjuvant chemoradiotherapy.
Pöttgen C, Levegrün S, Theegarten D, Marnitz S, Grehl S, Pink R, Eberhardt W, Stamatis G, Gauler T, Antoch G, Bockisch A, Stuschke M. Pöttgen C, et al. Among authors: theegarten d. Clin Cancer Res. 2006 Jan 1;12(1):97-106. doi: 10.1158/1078-0432.CCR-05-0510. Clin Cancer Res. 2006. PMID: 16397030 Free article.
Prognostic model for long-term survival of locally advanced non-small-cell lung cancer patients after neoadjuvant radiochemotherapy and resection integrating clinical and histopathologic factors.
Pöttgen C, Stuschke M, Graupner B, Theegarten D, Gauler T, Jendrossek V, Freitag L, Jawad JA, Gkika E, Wohlschlaeger J, Welter S, Hoiczyk M, Schuler M, Stamatis G, Eberhardt W. Pöttgen C, et al. Among authors: theegarten d. BMC Cancer. 2015 May 6;15:363. doi: 10.1186/s12885-015-1389-4. BMC Cancer. 2015. PMID: 25943191 Free PMC article.
Pretreatment metabolic tumour volume in stage IIIA/B non-small-cell lung cancer uncovers differences in effectiveness of definitive radiochemotherapy schedules: analysis of the ESPATUE randomized phase 3 trial.
Guberina M, Eberhardt W, Stuschke M, Gauler T, Aigner C, Schuler M, Stamatis G, Theegarten D, Jentzen W, Herrmann K, Pöttgen C. Guberina M, et al. Among authors: theegarten d. Eur J Nucl Med Mol Imaging. 2019 Jul;46(7):1439-1447. doi: 10.1007/s00259-019-4270-x. Epub 2019 Feb 1. Eur J Nucl Med Mol Imaging. 2019. PMID: 30710323 Clinical Trial.
Comparison of early tumour-associated versus late deaths in patients with central or >7 cm T4 N0/1 M0 non-small-cell lung-cancer undergoing trimodal treatment: Only few risks left to improve.
Guberina N, Pöttgen C, Schuler M, Guberina M, Stamatis G, Plönes T, Krebs B, Metzenmacher M, Theegarten D, Gauler T, Jöckel KH, Darwiche K, Aigner C, Stuschke M, Eberhardt WE. Guberina N, et al. Among authors: theegarten d. Eur J Cancer. 2020 Oct;138:156-168. doi: 10.1016/j.ejca.2020.07.025. Epub 2020 Sep 2. Eur J Cancer. 2020. PMID: 32889370
Accelerated hyperfractionated radiotherapy within trimodality therapy concepts for stage IIIA/B non-small cell lung cancer: Markedly higher rate of pathologic complete remissions than with conventional fractionation.
Pöttgen C, Eberhardt W, Graupner B, Theegarten D, Gauler T, Freitag L, Abu Jawad J, Wohlschlaeger J, Welter S, Stamatis G, Stuschke M. Pöttgen C, et al. Among authors: theegarten d. Eur J Cancer. 2013 Jun;49(9):2107-15. doi: 10.1016/j.ejca.2013.02.030. Epub 2013 Mar 16. Eur J Cancer. 2013. PMID: 23510803
10-year long-term survival (LTS) of induction chemotherapy with three cycles cisplatin/paclitaxel followed by concurrent chemoradiation cisplatin/etoposide/45 Gy (1.5 Gy bid) plus surgery in locally advanced non-small-cell lung cancer (NSCLC)-a multicenter phase-II trial (CISTAXOL).
Eberhardt WE, Gauler TC, Lepechoux C, Stamatis G, Bildat S, Krbek T, Welter S, Grunenwald D, Fischer B, Rodrigo Hde L, Theegarten D, Le Chevalier T, Seeber S, Stuschke M, Poettgen C. Eberhardt WE, et al. Among authors: theegarten d. Lung Cancer. 2013 Oct;82(1):83-9. doi: 10.1016/j.lungcan.2013.06.007. Epub 2013 Aug 16. Lung Cancer. 2013. PMID: 23957964 Clinical Trial.
Impact of EBUS-TBNA in addition to [18F]FDG-PET/CT imaging on target volume definition for radiochemotherapy in stage III NSCLC.
Guberina M, Darwiche K, Hautzel H, Ploenes T, Pöttgen C, Guberina N, Herrmann K, Umutlu L, Wetter A, Theegarten D, Aigner C, Eberhardt WEE, Schuler M, Karpf-Wissel R, Stuschke M. Guberina M, et al. Among authors: theegarten d. Eur J Nucl Med Mol Imaging. 2021 Aug;48(9):2894-2903. doi: 10.1007/s00259-021-05204-7. Epub 2021 Feb 5. Eur J Nucl Med Mol Imaging. 2021. PMID: 33547554 Free PMC article.
PROGNOSTIC VALUE OF POST-INDUCTION CHEMOTHERAPY VOLUMETRIC PET/CT PARAMETERS FOR STAGE IIIA/B NON-SMALL CELL LUNG CANCER PATIENTS RECEIVING DEFINITIVE CHEMORADIOTHERAPY.
Guberina M, Poettgen C, Metzenmacher M, Wiesweg M, Schuler M, Aigner C, Ploenes T, Umutlu L, Gauler T, Darwiche K, Stamatis G, Theegarten D, Hautzel H, Jentzen W, Guberina N, Herrmann K, Eberhardt WEE, Stuschke M. Guberina M, et al. Among authors: theegarten d. J Nucl Med. 2021 May 20;62(12):1684-91. doi: 10.2967/jnumed.120.260646. Online ahead of print. J Nucl Med. 2021. PMID: 34016730 Free PMC article.
184 results